Journal Article

Elaboration of Consensus Clinical Endpoints to Evaluate Antimicrobial Treatment Efficacy in Future Hospital-acquired/Ventilator-associated Bacterial Pneumonia Clinical Trials

Zahar, Jean-Ralph, De Waele, Jan, Talbot, George H., Bassetti, Matteo, Engelhardt, Marc, Weiss, Emmanuel, Rello, Jordi, Timsit, Jean-François, Alder, Jeff, Kollef, Marin, Ewig, Santiago, Dimopoulos, George, Martin-Loeches, Ignacio, Shorr, Andrew F., Thamlikitkul, Visanu, Asehnoune, Karim, Eggimann, Philippe, Torres, Antoni, Pagani, Leonardo, Poulakou, Garyphallia, Prokocimer, Philippe, Bonten, Marc J. M., Papazian, Laurent, Wunderink, Richard G., Lipman, Jeffrey, Luna, Carlos, Chastre, Jean, Rex, John H., Palmer, Lucy B.

2019

Overview

Abstract Background Randomized clinical trials (RCTs) in hospital-acquired and ventilator-associated bacterial pneumonia (HABP and VABP, respectively) are important for the evaluation of new antimicrobials. However, the heterogeneity in endpoints used in RCTs evaluating treatment of HABP/VABP may puzzle clinicians. The aim of this work was to reach a consensus on clinical endpoints to consider in future clinical trials evaluating antimicrobial treatment efficacy for HABP/VABP. Methods Twenty-six international experts from intensive care, infectious diseases, and the pharmaceutical industry were polled using the Delphi method. Results The panel recommended a hierarchical composite endpoint including, by priority order, (1) survival at day 28, (2) mechanical ventilation–free days through day 28, and (3) clinical cure between study days 7 and 10 for VABP; and (1) survival (day 28) and (2) clinical cure (days 7–10) for HABP. Clinical cure was defined as the combination of resolution of signs and symptoms present at enrollment and improvement or lack of progression of radiological signs. More than 70% of the experts agreed to assess survival and mechanical ventilation–free days though day 28, and clinical cure between day 7 and day 10 after treatment initiation. Finally, the hierarchical order of endpoint components was reached after 3 Delphi rounds (72% agreement). Conclusions We provide a multinational expert consensus on separate hierarchical composite endpoints for VABP and HABP, and on a definition of clinical cure that could be considered for use in future HABP/VABP clinical trials. Using the Delphi method, this study provides a multinational expert consensus on separate hierarchical composite endpoints for hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP), and on a definition of clinical cure that could be considered for use in future HABP/VABP clinical trials.

• Publisher: Oxford University Press
• Subject: and Commentaries / ARTICLES AND COMMENTARIES